Additionally, diabetes-associated alterations in serum biomarkers, including galectin-3, reflect ECM remodeling and contribute to diastolic dysfunction progression, highlighting the intricate interplay between galectin-3 and ECM dynamics in diabetic cardiomyopathy [28]. The gene discussed is LGALS3; the disease is diabetic cardiomyopathy.